Top Healthcare Market Research Companies in Spain (2026 Guide)

Spain is a strategically important pharmaceutical and healthcare market — with a healthcare system estimated at over €120 billion and a pharmaceutical market of over €20 billion in 2026. As Europe's fourth-largest pharmaceutical market and a key EU5 reference market, Spain is a priority for global pharmaceutical and biotech companies — particularly for oncology, immunology, rheumatology, and rare disease pipeline programmes.

Healthcare market research in Spain is shaped by three defining structural features:

• Decentralised Autonomous Community payer landscape: Spain's universal SNS is implemented through 17 Autonomous Communities, each managing independent healthcare budgets and formulary criteria. National CIPM pricing and SNS reimbursement listing by the Ministerio de Sanidad does not guarantee regional access — Catalonia (CatSalut/PHF), Madrid (SERMAS), and Andalucía (SAS) each apply additional formulary criteria and adoption timelines creating significant post-listing access variation. This is the defining structural feature that distinguishes Spain from all other EU5 markets.
• GENESIS hospital pharmacy committee system: The GENESIS pharmacoeconomic evaluation system — developed by the Sociedad Española de Farmacia Hospitalaria (SEFH) — is used by hospital pharmacy and therapeutics committees across Spain for hospital formulary inclusion decisions. Hospital-administered therapies in oncology, rheumatology, and rare disease must satisfy GENESIS evidence requirements before reaching patients at major Spanish university hospitals. No equivalent system exists in Germany, France, Italy, or the UK.
• Spanish-language fieldwork imperative: All primary HCP and patient research in Spain requires Spanish-language fieldwork — with bilingual (Spanish/English) deliverables for global pharmaceutical clients. Regional language capability (Catalan, Basque, Galician) may add credibility for specific community research. Research without in-country Spanish-language execution produces materially lower HCP engagement and response quality.

For additional Spain pharmaceutical context, see our Spain pharmaceutical market research guide.

Spain's hospital network concentrates the country's most influential specialist KOLs within a set of major university hospitals in five key cities: Hospital Clínic Barcelona — Spain's leading academic clinical centre with major oncology, hepatology, and infectious disease KOL concentration; Hospital Universitari Vall d'Hebron — Barcelona's largest teaching hospital, with strong oncology, rare disease, and neurology KOL density; Hospital Universitario La Paz (Madrid) — a major academic centre with broad specialist coverage and strong rheumatology and oncology influence; Hospital Universitario 12 de Octubre (Madrid) — the key oncology, cardiovascular, and transplant KOL hub for central Spain; and Hospital Universitario Virgen del Rocío (Seville) — the primary academic centre for southern Spain and Andalucía with major regional influence. Clínica Universidad de Navarra is a leading private academic medical centre with national oncology, rare disease, and clinical research influence.

KOL mapping in Spain requires tracking influence across three tiers: national KOLs at leading university hospitals and specialist societies (SEOM, SEMI, SER, SEC, SEN); regional Autonomous Community KOLs with formulary committee influence; and local hospital-level prescribers who drive early adoption at their institutions. Spanish specialist societies set national clinical guidelines that shape prescribing behaviour — SEOM guidelines in oncology, SEC guidelines in cardiology, and SER guidelines in rheumatology are particularly influential in shaping treatment algorithm positions.

HCP surveys in Spain require Spanish-language discussion guides and fieldwork, verified physician recruitment, and coverage across both hospital specialists and primary care physicians in all 17 Autonomous Communities. Bilingual (Spanish/English) deliverables are standard for global pharma clients running EU5 programmes that include Spain.

BioNixus conducts KOL mapping and HCP research across Spain in oncology, cardiovascular, rheumatology, immunology, metabolic, rare disease, and other specialty areas — with Spanish-language fieldwork, bilingual deliverables, and EU5 regional benchmarking. See our Spain pharmaceutical market research guide for methodology details.